青蒿素抗疟药市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023 年，全球青蒿素抗疟药物市场价值为 6.722 亿美元，预计 2024 年至 2032 年复合年增长率为 4.2%。例如，美国疾病管制与预防中心报告称，2022年，全球约有2.49亿疟疾病例，导致60.8万人死亡。这些令人震惊的统计数据凸显了对有效治疗的需求增加，推动了青蒿素抗疟药物市场的成长。

基于青蒿素的联合疗法（ACT）作为疟疾治疗的黄金标准的崛起在市场扩张中发挥了关键作用。持续的研究和开发工作旨在增强这些药物的功效和安全性。疟疾诊断的进步进一步刺激了市场成长。在世界卫生组织等国际实体的支持下，全球对消除疟疾的承诺凸显了市场的重要性。此外，人们对疟疾早期诊断和治疗认识的提高扩大了对青蒿素疗法的需求，推动了市场的发展势头。

整个青蒿素抗疟药物产业根据疟疾类型、产品、类型和地区进行细分。

2023 年，恶性疟原虫细分市场以 5.538 亿美元的估值引领市场。作为毒性最强的引起疟疾的寄生虫，恶性疟原虫由于其普遍且严重的感染而占有相当大的市场份额。鑑于其在清除寄生虫和降低死亡率方面的快速功效，基于青蒿素的联合疗法（ACT）成为恶性疟原虫疟疾的第一线治疗方法。恶性疟原虫疟疾的显着负担，特别是在撒哈拉以南非洲和东南亚，刺激了对这些治疗方法的需求。因此，青蒿素抗疟药物市场主要是由解决恶性疟原虫的必要性决定的，从而巩固了其在治疗领域的主导地位。

到了2023年，抗疟药片细分市场占据80.5%的主导市场份额，这主要是由于其在疟疾治疗中的广泛应用和已被证明的疗效。这些片剂由蒿甲醚和苯芴醇等强效青蒿素衍生物配製而成，因其强大的抗疟作用和易于服用而受到青睐。它们融入国民治疗指南，再加上公共卫生系统和私人市场的可用性，巩固了其领先的市场地位。

2023 年，中东和非洲市场价值为2.315 亿美元，预计2024 年至2032 年复合年增长率为4.1%。流行的疟疾病例。在政府和非政府组织的支持下，正在进行的抗击疟疾的健康措施增强了市场的存在。对医疗保健基础设施的投资、疟疾预防意识的提高以及以青蒿素为基础的联合疗法 (ACT) 的可及性的提高，进一步扩大了该地区的市场份额。这些要素，加上加强治疗效果和药物可近性的策略重点，凸显了中东和非洲地区在全球市场中的关键角色。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 疟疾盛行率高
    • 国际组织的支持
    • 提高认识和诊断
  • 产业陷阱与挑战
    • 生产成本高
    • 替代治疗的可用性
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按疟疾类型，2021 - 2032 年

• 主要趋势
• 恶性疟原虫
• 间日疟原虫
• 卵形疟原虫
• 三日疟原虫
• 诺氏疟原虫

第 6 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 抗疟注射剂
• 抗疟药片

第 7 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 单一疗法
• 合併治疗

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AdvaCare Pharma USA LLC
• Calyx Chemicals and Pharmaceuticals Ltd.
• Cipla Limited
• Guilin Pharmaceutical Co., Ltd.
• Ipca Laboratories Ltd.
• KPC Pharmaceuticals, Inc.
• Novartis AG
• Rusan Pharma Ltd.
• Sanofi S.A.
• Shin Poong Pharmaceutical Co., Ltd.

The Global Artemisinin Antimalarial Drugs Market was valued at USD 672.2 million in 2023 and is projected to grow at a CAGR of 4.2% from 2024 to 2032. The demand for effective malaria treatments has surged, especially in tropical and subtropical regions, due to the rising incidence of the disease. For example, the CDC reported that in 2022, there were approximately 249 million global malaria cases, resulting in 608,000 deaths. These alarming statistics underscore the heightened demand for effective treatments, propelling the growth of the artemisinin antimalarial drugs market.

The rise of artemisinin-based combination therapies (ACTs) as the gold standard for malaria treatment has played a pivotal role in market expansion. Continuous research and development efforts aim to bolster the efficacy and safety profiles of these drugs. Advancements in malaria diagnostics further stimulate market growth. The global commitment to eradicating malaria, supported by international entities like the World Health Organization, underscores the market's significance. Additionally, heightened awareness regarding early malaria diagnosis and treatment amplifies the demand for artemisinin-based therapies, propelling the market's momentum.

The overall artemisinin antimalarial drugs industry is segmented based on malaria type, product, type, and region.

In 2023, the Plasmodium falciparum segment led the market with a valuation of USD 553.8 million. As the most virulent malaria-causing parasite, Plasmodium falciparum commands a substantial market share due to its prevalent and severe infections. Given their rapid efficacy in clearing the parasite and reducing mortality, artemisinin-based combination therapies (ACTs) serve as the frontline treatment for P. falciparum malaria. The pronounced burden of P. falciparum malaria, especially in Sub-Saharan Africa and Southeast Asia, fuels the demand for these treatments. Thus, the artemisinin antimalarial drugs market is predominantly shaped by the imperative to address P. falciparum, solidifying its leading role in the therapeutic domain.

The antimalarial tablets segment commanded a dominant market share of 80.5% in 2023, largely due to their widespread application and proven efficacy in malaria treatment. Formulated with potent artemisinin derivatives like artemether and lumefantrine, these tablets are favored for their robust antimalarial effects and ease of administration. Their integration into national treatment guidelines, coupled with availability across public health systems and private markets, cements their leading market position.

In 2023, the Middle East and Africa market was valued at USD 231.5 million and is projected to grow at a CAGR of 4.1% from 2024 to 2032. The MEA region's substantial share in the artemisinin antimalarial drugs market is attributed to the prevalent malaria cases in several of its countries. Ongoing health initiatives to combat malaria, supported by governmental and non-governmental organizations, fortify the market's presence. Investments in healthcare infrastructure, heightened awareness of malaria prevention, and increased accessibility to artemisinin-based combination therapies (ACTs) further amplify the region's market share. These elements, alongside a strategic emphasis on enhancing treatment outcomes and drug accessibility, highlight the MEA region's pivotal role in the global market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 High prevalence of malaria
    • 3.2.1.2 Support from international organizations
    • 3.2.1.3 Increased awareness and diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of production
    • 3.2.2.2 Availability of alternative treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Malaria Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Plasmodium falciparum
• 5.3 Plasmodium vivax
• 5.4 Plasmodium ovale
• 5.5 Plasmodium malariae
• 5.6 Plasmodium knowlesi

Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Antimalarial injections
• 6.3 Antimalarial tablets

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Monotherapy
• 7.3 Combination therapy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AdvaCare Pharma USA LLC
• 9.2 Calyx Chemicals and Pharmaceuticals Ltd.
• 9.3 Cipla Limited
• 9.4 Guilin Pharmaceutical Co., Ltd.
• 9.5 Ipca Laboratories Ltd.
• 9.6 KPC Pharmaceuticals, Inc.
• 9.7 Novartis AG
• 9.8 Rusan Pharma Ltd.
• 9.9 Sanofi S.A.
• 9.10 Shin Poong Pharmaceutical Co., Ltd.